Targeting a specific enzyme to fight a type of lymphoma linked to a virus

Targeting IKKepsilon-mediated nucleotide synthesis in KSHV-associated lymphoma

NIH-funded research University of Southern California · NIH-10879181

This study is looking at how a specific enzyme called IKKepsilon helps cancer cells grow when they are infected with a virus linked to certain lymphomas, and it aims to find new treatments that could stop this growth for people dealing with these types of cancers.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Southern California NIH-funded
Lab location1 site (Los Angeles, UNITED STATES)
Project IDNIH-10879181 on NIH RePORTER

What this research studies

This research investigates how the IKKepsilon enzyme is involved in the metabolism of cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV), which can lead to certain types of lymphoma. The study aims to understand the molecular mechanisms by which KSHV manipulates this enzyme to promote cancer cell growth. Researchers will develop and test new small-molecule inhibitors that target IKKepsilon and related metabolic processes to potentially halt the proliferation of these cancerous cells. By focusing on the virus-host interactions, the research seeks to find innovative treatment options for patients suffering from KSHV-associated malignancies.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals diagnosed with KSHV-associated lymphomas, particularly those who are immunocompromised, such as AIDS patients.

Not a fit: Patients with lymphomas not associated with KSHV or those who are not immunocompromised may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic options for patients with KSHV-associated lymphomas, improving their treatment outcomes.

How similar studies have performed: While targeting metabolic pathways in cancer is a growing field, this specific approach to targeting IKKepsilon in KSHV-associated lymphoma is relatively novel and has not been extensively tested.

Where this research is happening

Los Angeles, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency SyndromeAcquired Immunodeficiency SyndromeCancers
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.